BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Limpaiboon T, Khaenam P, Chinnasri P, Soonklang M, Jearanaikoon P, Sripa B, Pairojkul C, Bhudhisawasdi V. Promoter hypermethylation is a major event of hMLH1 gene inactivation in liver fluke related cholangiocarcinoma. Cancer Lett. 2005;217:213-219. [PMID: 15617839 DOI: 10.1016/j.canlet.2004.06.020] [Cited by in Crossref: 27] [Cited by in F6Publishing: 77] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Kim M, Delgado E, Ko S. DNA methylation in cell plasticity and malignant transformation in liver diseases. Pharmacol Ther 2023;241:108334. [PMID: 36535346 DOI: 10.1016/j.pharmthera.2022.108334] [Reference Citation Analysis]
2 Rogalska-Taranta M, Andersen JB. Involvement of Epigenomic Factors in Bile Duct Cancer. Semin Liver Dis 2022;42:202-11. [PMID: 35738258 DOI: 10.1055/s-0042-1748188] [Reference Citation Analysis]
3 García-sampedro A, Acedo P, Pereira SP. Established and Emerging Biomarkers for Prediction, Early Detection, and Prognostication of Cholangiocarcinoma. Diagnosis and Management of Cholangiocarcinoma 2021. [DOI: 10.1007/978-3-030-70936-5_19] [Reference Citation Analysis]
4 Vedeld HM, Folseraas T, Lind GE. Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis - The promise of DNA methylation and molecular biomarkers.JHEP Rep. 2020;2:100143. [PMID: 32939446 DOI: 10.1016/j.jhepr.2020.100143] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
5 Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF, Perugorria MJ, Fabris L, Boulter L, Macias RIR, Gaudio E, Alvaro D, Gradilone SA, Strazzabosco M, Marzioni M, Coulouarn C, Fouassier L, Raggi C, Invernizzi P, Mertens JC, Moncsek A, Rizvi S, Heimbach J, Koerkamp BG, Bruix J, Forner A, Bridgewater J, Valle JW, Gores GJ. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol 2020;17:557-88. [PMID: 32606456 DOI: 10.1038/s41575-020-0310-z] [Cited by in Crossref: 622] [Cited by in F6Publishing: 599] [Article Influence: 207.3] [Reference Citation Analysis]
6 Intuyod K, Armartmuntree N, Jusakul A, Sakonsinsiri C, Thanan R, Pinlaor S. Current omics-based biomarkers for cholangiocarcinoma. Expert Rev Mol Diagn 2019;19:997-1005. [PMID: 31566016 DOI: 10.1080/14737159.2019.1673162] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Rai V, Boosani C, Agrawal D. The promising role of epigenetic mediators and microRNAs in the early diagnosis of cholangiocarcinoma (Review). Wrld Acd Sci 2019. [DOI: 10.3892/wasj.2019.18] [Reference Citation Analysis]
8 Gurmikov BN, Kovalenko YA, Vishnevsky VA, Chzhao AV. Molecular genetic aspects of intrahepatic cholangiocarcinoma: literature review. Usp mol onkol 2019;6:37-43. [DOI: 10.17650/2313-805x-2019-6-1-37-43] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
9 Rajagopalan D, Jha S. An epi(c)genetic war: Pathogens, cancer and human genome. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2018;1869:333-45. [DOI: 10.1016/j.bbcan.2018.04.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
10 Nakaoka T, Saito Y, Saito H. Aberrant DNA Methylation as a Biomarker and a Therapeutic Target of Cholangiocarcinoma. Int J Mol Sci. 2017;18:1111. [PMID: 28545228 DOI: 10.3390/ijms18061111] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 4.3] [Reference Citation Analysis]
11 Serafini FM, Radvinsky D. The pathways of genetic transformation in cholangiocarcinogenesis. Cancer Genet 2016;209:554-8. [PMID: 27720541 DOI: 10.1016/j.cancergen.2016.07.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
12 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RI, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJ, Alvaro D. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [PMID: 27095655 DOI: 10.1038/nrgastro.2016.51] [Cited by in Crossref: 731] [Cited by in F6Publishing: 690] [Article Influence: 104.4] [Reference Citation Analysis]
13 Chiang NJ, Shan YS, Hung WC, Chen LT. Epigenetic regulation in the carcinogenesis of cholangiocarcinoma. Int J Biochem Cell Biol. 2015;67:110-114. [PMID: 26100596 DOI: 10.1016/j.biocel.2015.06.012] [Cited by in Crossref: 13] [Cited by in F6Publishing: 60] [Article Influence: 1.6] [Reference Citation Analysis]
14 Jusakul A, Kongpetch S, Teh BT. Genetics of Opisthorchis viverrini-related cholangiocarcinoma. Curr Opin Gastroenterol 2015;31:258-63. [PMID: 25693006 DOI: 10.1097/MOG.0000000000000162] [Cited by in Crossref: 35] [Cited by in F6Publishing: 40] [Article Influence: 4.4] [Reference Citation Analysis]
15 Janvilisri T, Leelawat K, Roytrakul S, Paemanee A, Tohtong R. Novel Serum Biomarkers to Differentiate Cholangiocarcinoma from Benign Biliary Tract Diseases Using a Proteomic Approach. Dis Markers. 2015;2015:105358. [PMID: 26060332 DOI: 10.1155/2015/105358] [Cited by in Crossref: 19] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
16 Maroni L, Pierantonelli I, Banales JM, Benedetti A, Marzioni M. The significance of genetics for cholangiocarcinoma development. Ann Transl Med 2013;1:28. [PMID: 25332972 DOI: 10.3978/j.issn.2305-5839.2012.10.04] [Cited by in F6Publishing: 17] [Reference Citation Analysis]
17 Ushijima T, Takeshima H. Epigenetic Epidemiology of Infectious Diseases. Epigenetic Epidemiology 2012. [DOI: 10.1007/978-94-007-2495-2_14] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
18 Sriraksa R, Zeller C, El-Bahrawy MA, Dai W, Daduang J, Jearanaikoon P, Chau-In S, Brown R, Limpaiboon T. CpG-island methylation study of liver fluke-related cholangiocarcinoma. Br J Cancer. 2011;104:1313-1318. [PMID: 21448164 DOI: 10.1038/bjc.2011.102] [Cited by in Crossref: 34] [Cited by in F6Publishing: 40] [Article Influence: 2.8] [Reference Citation Analysis]
19 Vaiserman AM, Voitenko VP, Mekhova LV. Epigenetic epidemiology of age-related diseases. Russ J Dev Biol 2011;42:25-42. [DOI: 10.1134/s1062360411010127] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
20 Alpini GD, Francis HL, Marzioni M, Alvaro D, Gaudio E, Lorenzini I, Benedetti A, Fava G. Cholangiocarcinoma. Molecular Pathology Library 2011. [DOI: 10.1007/978-1-4419-7107-4_59] [Reference Citation Analysis]
21 Huang L, Frampton G, Liang LJ, DeMorrow S. Aberrant DNA methylation profile in cholangiocarcinoma. World J Gastrointest Pathophysiol 2010; 1(2): 23-29 [PMID: 21607139 DOI: 10.4291/wjgp.v1.i2.23] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
22 Jain D, Ahrens W, Finkelstein S. Molecular evidence for the neoplastic potential of hepatic Von-Meyenburg complexes. Appl Immunohistochem Mol Morphol. 2010;18:166-171. [PMID: 19770706 DOI: 10.1097/pai.0b013e3181b94fd8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
23 Thanasai J, Limpaiboon T, Jearanaikoon P, Sripa B, Pairojkul C, Tantimavanich S, Miwa M. Effects of thymidine phosphorylase on tumor aggressiveness and 5-fluorouracil sensitivity in cholangiocarcinoma. World J Gastroenterol 2010; 16(13): 1631-1638 [PMID: 20355241 DOI: 10.3748/wjg.v16.i13.1631] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
24 Khaenam P, Jearanaikoon P, Pairojkul C, Bhudhisawasdi V, Limpaiboon T. Genetic and epigenetic alterations of RIZ1 and the correlation to clinicopathological parameters in liver fluke-related cholangiocarcinoma.Exp Ther Med. 2010;1:385-390. [PMID: 22993552 DOI: 10.3892/etm_00000060] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
25 Chinnasri P, Pairojkul C, Jearanaikoon P, Sripa B, Bhudhisawasdi V, Tantimavanich S, Limpaiboon T. Preferentially different mechanisms of inactivation of 9p21 gene cluster in liver fluke–related cholangiocarcinoma. Human Pathology 2009;40:817-26. [DOI: 10.1016/j.humpath.2008.11.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
26 Vuillermin PJ, Ponsonby AL, Saffery R, Tang ML, Ellis JA, Sly P, Holt P. Microbial exposure, interferon gamma gene demethylation in naïve T-cells, and the risk of allergic disease. Allergy 2009;64:348-53. [PMID: 19210359 DOI: 10.1111/j.1398-9995.2009.01970.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 65] [Article Influence: 4.5] [Reference Citation Analysis]
27 Foley DL, Craig JM, Morley R, Olsson CA, Dwyer T, Smith K, Saffery R. Prospects for epigenetic epidemiology. Am J Epidemiol 2009;169:389-400. [PMID: 19139055 DOI: 10.1093/aje/kwn380] [Cited by in Crossref: 173] [Cited by in F6Publishing: 190] [Article Influence: 12.4] [Reference Citation Analysis]
28 Sandhu DS, Shire AM, Roberts LR. Epigenetic DNA hypermethylation in cholangiocarcinoma: potential roles in pathogenesis, diagnosis and identification of treatment targets. Liver Int 2008;28:12-27. [PMID: 18031477 DOI: 10.1111/j.1478-3231.2007.01624.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 43] [Article Influence: 2.3] [Reference Citation Analysis]
29 Tischoff I, Wittekind C, Tannapfel A. Role of epigenetic alterations in cholangiocarcinoma. J Hepatobiliary Pancreat Surg. 2006;13:274-279. [PMID: 16858537 DOI: 10.1007/s00534-005-1055-3] [Cited by in Crossref: 32] [Cited by in F6Publishing: 39] [Article Influence: 2.0] [Reference Citation Analysis]
30 Thanasai J, Limpaiboon T, Jearanaikoon P, Bhudhisawasdi V, Khuntikeo N, Sripa B, Miwa M. Amplification of D22S283 as a favorable prognostic indicator in liver fluke related cholangiocarcinoma. World J Gastroenterol 2006; 12(27): 4338-4344 [PMID: 16865775 DOI: 10.3748/wjg.v12.i27.4338] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]